Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection

Gaya Spolverato, Yuhree Kim, Sorin Alexandrescu, Hugo P. Marques, Jorge Lamelas, Luca Aldrighetti, T. Clark Gamblin, Shishir K. Maithel, Carlo Pulitano, Todd W. Bauer, Feng Shen, George A. Poultsides, Thuy B. Tran, J. Wallis Marsh, Timothy M. Pawlik

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma (ICC) following curative-intent surgery are not well documented. We sought to characterize the treatment of patients with recurrent ICC and define therapy-specific outcomes. Methods: Patients who underwent surgery for ICC from 1990 to 2013 were identified from an international database. Data on clinicopathological characteristics, operative details, recurrence, and recurrence-related management were recorded and analyzed. Results: A total of 563 patients undergoing curative-intent hepatic resection for ICC who met the inclusion criteria were identified. With a median follow-up of 19 months, 400 (71.0 %) patients developed a recurrence. At initial surgery, treatment was resection only (98.8 %) or resection + ablation (1.2 %). Overall 5-year survival was 23.6 %; 400 (71.0 %) patients recurred with a median disease-free survival of 11.2 months. First recurrence site was intrahepatic only (59.8 %), extrahepatic only (14.5 %), or intra- and extrahepatic (25.7 %). Overall, 210 (52.5 %) patients received best supportive care (BSC), whereas 190 (47.5 %) patients received treatment, such as systemic chemotherapy-only (24.2 %) or repeat liver-directed therapy ± systemic chemotherapy (75.8 %). Repeat liver-directed therapy consisted of repeat hepatic resection ± ablation (28.5 %), ablation alone (18.7 %), and intra-arterial therapy (IAT) (52.8 %). Among patients who recurred, median survival from the time of the recurrence was 11.1 months (BSC 8.0 months, systemic chemotherapy-only 16.8 months, liver-directed therapy 18.0 months). The median survival of patients undergoing resection of recurrent ICC was 26.7 months versus 9.6 months for patients who had IAT (p <0.001). Conclusions: Recurrence following resection of ICC was common, occurring in up to two-thirds of patients. When there is recurrence, prognosis is poor. Only 9 % of patients underwent repeat liver resection after recurrence, which offered a modest survival benefit.

Original languageEnglish
Pages (from-to)235-243
Number of pages9
JournalAnnals of Surgical Oncology
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Cholangiocarcinoma
Recurrence
Liver
Therapeutics
Survival
Drug Therapy
Disease-Free Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. / Spolverato, Gaya; Kim, Yuhree; Alexandrescu, Sorin; Marques, Hugo P.; Lamelas, Jorge; Aldrighetti, Luca; Clark Gamblin, T.; Maithel, Shishir K.; Pulitano, Carlo; Bauer, Todd W.; Shen, Feng; Poultsides, George A.; Tran, Thuy B.; Wallis Marsh, J.; Pawlik, Timothy M.

In: Annals of Surgical Oncology, Vol. 23, No. 1, 01.01.2016, p. 235-243.

Research output: Contribution to journalArticle

Spolverato, G, Kim, Y, Alexandrescu, S, Marques, HP, Lamelas, J, Aldrighetti, L, Clark Gamblin, T, Maithel, SK, Pulitano, C, Bauer, TW, Shen, F, Poultsides, GA, Tran, TB, Wallis Marsh, J & Pawlik, TM 2016, 'Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection', Annals of Surgical Oncology, vol. 23, no. 1, pp. 235-243. https://doi.org/10.1245/s10434-015-4642-9
Spolverato, Gaya ; Kim, Yuhree ; Alexandrescu, Sorin ; Marques, Hugo P. ; Lamelas, Jorge ; Aldrighetti, Luca ; Clark Gamblin, T. ; Maithel, Shishir K. ; Pulitano, Carlo ; Bauer, Todd W. ; Shen, Feng ; Poultsides, George A. ; Tran, Thuy B. ; Wallis Marsh, J. ; Pawlik, Timothy M. / Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. In: Annals of Surgical Oncology. 2016 ; Vol. 23, No. 1. pp. 235-243.
@article{497cb84b87104193a76edefa88cd78dc,
title = "Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection",
abstract = "Background: Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma (ICC) following curative-intent surgery are not well documented. We sought to characterize the treatment of patients with recurrent ICC and define therapy-specific outcomes. Methods: Patients who underwent surgery for ICC from 1990 to 2013 were identified from an international database. Data on clinicopathological characteristics, operative details, recurrence, and recurrence-related management were recorded and analyzed. Results: A total of 563 patients undergoing curative-intent hepatic resection for ICC who met the inclusion criteria were identified. With a median follow-up of 19 months, 400 (71.0 {\%}) patients developed a recurrence. At initial surgery, treatment was resection only (98.8 {\%}) or resection + ablation (1.2 {\%}). Overall 5-year survival was 23.6 {\%}; 400 (71.0 {\%}) patients recurred with a median disease-free survival of 11.2 months. First recurrence site was intrahepatic only (59.8 {\%}), extrahepatic only (14.5 {\%}), or intra- and extrahepatic (25.7 {\%}). Overall, 210 (52.5 {\%}) patients received best supportive care (BSC), whereas 190 (47.5 {\%}) patients received treatment, such as systemic chemotherapy-only (24.2 {\%}) or repeat liver-directed therapy ± systemic chemotherapy (75.8 {\%}). Repeat liver-directed therapy consisted of repeat hepatic resection ± ablation (28.5 {\%}), ablation alone (18.7 {\%}), and intra-arterial therapy (IAT) (52.8 {\%}). Among patients who recurred, median survival from the time of the recurrence was 11.1 months (BSC 8.0 months, systemic chemotherapy-only 16.8 months, liver-directed therapy 18.0 months). The median survival of patients undergoing resection of recurrent ICC was 26.7 months versus 9.6 months for patients who had IAT (p <0.001). Conclusions: Recurrence following resection of ICC was common, occurring in up to two-thirds of patients. When there is recurrence, prognosis is poor. Only 9 {\%} of patients underwent repeat liver resection after recurrence, which offered a modest survival benefit.",
author = "Gaya Spolverato and Yuhree Kim and Sorin Alexandrescu and Marques, {Hugo P.} and Jorge Lamelas and Luca Aldrighetti and {Clark Gamblin}, T. and Maithel, {Shishir K.} and Carlo Pulitano and Bauer, {Todd W.} and Feng Shen and Poultsides, {George A.} and Tran, {Thuy B.} and {Wallis Marsh}, J. and Pawlik, {Timothy M.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1245/s10434-015-4642-9",
language = "English",
volume = "23",
pages = "235--243",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection

AU - Spolverato, Gaya

AU - Kim, Yuhree

AU - Alexandrescu, Sorin

AU - Marques, Hugo P.

AU - Lamelas, Jorge

AU - Aldrighetti, Luca

AU - Clark Gamblin, T.

AU - Maithel, Shishir K.

AU - Pulitano, Carlo

AU - Bauer, Todd W.

AU - Shen, Feng

AU - Poultsides, George A.

AU - Tran, Thuy B.

AU - Wallis Marsh, J.

AU - Pawlik, Timothy M.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma (ICC) following curative-intent surgery are not well documented. We sought to characterize the treatment of patients with recurrent ICC and define therapy-specific outcomes. Methods: Patients who underwent surgery for ICC from 1990 to 2013 were identified from an international database. Data on clinicopathological characteristics, operative details, recurrence, and recurrence-related management were recorded and analyzed. Results: A total of 563 patients undergoing curative-intent hepatic resection for ICC who met the inclusion criteria were identified. With a median follow-up of 19 months, 400 (71.0 %) patients developed a recurrence. At initial surgery, treatment was resection only (98.8 %) or resection + ablation (1.2 %). Overall 5-year survival was 23.6 %; 400 (71.0 %) patients recurred with a median disease-free survival of 11.2 months. First recurrence site was intrahepatic only (59.8 %), extrahepatic only (14.5 %), or intra- and extrahepatic (25.7 %). Overall, 210 (52.5 %) patients received best supportive care (BSC), whereas 190 (47.5 %) patients received treatment, such as systemic chemotherapy-only (24.2 %) or repeat liver-directed therapy ± systemic chemotherapy (75.8 %). Repeat liver-directed therapy consisted of repeat hepatic resection ± ablation (28.5 %), ablation alone (18.7 %), and intra-arterial therapy (IAT) (52.8 %). Among patients who recurred, median survival from the time of the recurrence was 11.1 months (BSC 8.0 months, systemic chemotherapy-only 16.8 months, liver-directed therapy 18.0 months). The median survival of patients undergoing resection of recurrent ICC was 26.7 months versus 9.6 months for patients who had IAT (p <0.001). Conclusions: Recurrence following resection of ICC was common, occurring in up to two-thirds of patients. When there is recurrence, prognosis is poor. Only 9 % of patients underwent repeat liver resection after recurrence, which offered a modest survival benefit.

AB - Background: Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma (ICC) following curative-intent surgery are not well documented. We sought to characterize the treatment of patients with recurrent ICC and define therapy-specific outcomes. Methods: Patients who underwent surgery for ICC from 1990 to 2013 were identified from an international database. Data on clinicopathological characteristics, operative details, recurrence, and recurrence-related management were recorded and analyzed. Results: A total of 563 patients undergoing curative-intent hepatic resection for ICC who met the inclusion criteria were identified. With a median follow-up of 19 months, 400 (71.0 %) patients developed a recurrence. At initial surgery, treatment was resection only (98.8 %) or resection + ablation (1.2 %). Overall 5-year survival was 23.6 %; 400 (71.0 %) patients recurred with a median disease-free survival of 11.2 months. First recurrence site was intrahepatic only (59.8 %), extrahepatic only (14.5 %), or intra- and extrahepatic (25.7 %). Overall, 210 (52.5 %) patients received best supportive care (BSC), whereas 190 (47.5 %) patients received treatment, such as systemic chemotherapy-only (24.2 %) or repeat liver-directed therapy ± systemic chemotherapy (75.8 %). Repeat liver-directed therapy consisted of repeat hepatic resection ± ablation (28.5 %), ablation alone (18.7 %), and intra-arterial therapy (IAT) (52.8 %). Among patients who recurred, median survival from the time of the recurrence was 11.1 months (BSC 8.0 months, systemic chemotherapy-only 16.8 months, liver-directed therapy 18.0 months). The median survival of patients undergoing resection of recurrent ICC was 26.7 months versus 9.6 months for patients who had IAT (p <0.001). Conclusions: Recurrence following resection of ICC was common, occurring in up to two-thirds of patients. When there is recurrence, prognosis is poor. Only 9 % of patients underwent repeat liver resection after recurrence, which offered a modest survival benefit.

UR - http://www.scopus.com/inward/record.url?scp=84952631066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952631066&partnerID=8YFLogxK

U2 - 10.1245/s10434-015-4642-9

DO - 10.1245/s10434-015-4642-9

M3 - Article

AN - SCOPUS:84952631066

VL - 23

SP - 235

EP - 243

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 1

ER -